Company intelligence / Profile preview

Guangxi Wuzhou Zhongheng Group

Wuzhou, Guangxi, China

Ownership: Private
Employees: ~2971
Development stage: Phase 2

Overview

The company has a broad portfolio of approved drugs in China, including traditional Chinese medicines and modern pharmaceuticals for a wide range of indications such as cardiovascular, neurology, oncology, infectious disease, gynecology, ophthalmology and more. Several products are approved for use in China; some have been on the market since the early/mid–1980s or later.

Therapeutic areas: NephrologyPulmonologyInfectious DiseasesEndocrinologyOncologyHematologyOtherCardiovascularOphthalmologyNeurologyWomen's Health
Modalities: Small moleculeHerbal medicineProbioticsTherapeutic vaccineTCR-T cell therapyFluorescent dyes
Industry: Pharma

Drug pipeline

1 asset

VAL-083

Commercial

Indications: Chronic myelogenous leukemia, Lung cancer

Beyond the preview

Go deeper on Guangxi Wuzhou Zhongheng Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangxi Wuzhou Zhongheng Group.

Explore the full profile